U.S. FDA Extends Review Period for Expanded Use of AbbVie's Arthritis Drug Rinvoq

REFILE-UPDATE 1-U.S. FDA extends review period for expanded use of Abbvie's arthritis drug

The U.S. FDA has extended the review period for AbbVie's application to expand the use of its rheumatoid arthritis drug Rinvoq to patients with active psoriatic arthritis by three months. Rinvoq was approved for the treatment of rheumatoid arthritis in 2019. The FDA is also reviewing the expanded use of Rinvoq in atopic dermatitis and has sought additional information, which Abbvie plans to provide shortly.

AbbVie Inc.

AbbVie Inc. Expected to Maintain Market Position in Global Biopharmaceuticals Market

Biopharmaceuticals Market is Set To Fly High in Years to Come | Major Giants Pfizer, AbbVie, Johnson & Johnson ...

According to a market analysis, AbbVie Inc. is expected to maintain its market position in the Global Biopharmaceuticals Market over the next few years, along with other major players such as Pfizer, Johnson & Johnson Services, and Bristol-Myers Squibb Company.

AbbVie to Acquire Cerevel Therapeutics for $45.00 per Share

CERE SHAREHOLDERS: Cerevel Shareholders are Encouraged to Inquire About BFA Law's Investigation into the $45 ...

AbbVie, Inc. has agreed to acquire all outstanding shares of Cerevel Therapeutics for $45.00 per share in cash, valuing Cerevel Therapeutics at a total equity value of approximately $8.7 billion. The acquisition is currently under investigation by Bleichmar Fonti & Auld LLP, suspecting that Cerevel Therapeutics' board of directors may have been conflicted and agreed to an unfair amount to be paid to shareholders.

AbbVie's Stock Falls into Correction

AbbVie: Turnaround Lurking After The Correction Pain (Upgrade) (NYSE:ABBV)

Prediction: Eli Lilly's Latest Move Will Threaten AbbVie Stock

Cigna's Express Scripts unit moves away from AbbVie's Humira

AbbVie Inc.'s stock fell by nearly 16% since March 2024 highs, entering a correction phase.

Solid Earnings Scorecard in April 2024

AbbVie Inc. posted a solid earnings scorecard in April 2024, despite facing biosimilar erosion of its successful immunology drug, Humira.

AbbVie's Turnaround Gaining Momentum

3 Dividend Stocks to Double Up on Right Now

AbbVie Inc.'s turnaround could be gaining momentum, driven by skyrocketing sales of Skyrizi and Rinvoq, a solid oncology lineup, and a new CEO.

AbbVie's Q1 2024 Earnings Exceed Expectations

AbbVie: This Dividend Aristocrat Is Almost Buyable Again Now (NYSE:ABBV)

AbbVie reported a 0.7% year-over-year growth in net revenue to $12.3 billion, surpassing analyst consensus by $370 million. The company's long-term debt remains A-rated by S&P with a stable outlook.

Q2 2024 EPS Estimates Lowered by Analyst

Q2 2024 EPS Estimates for AbbVie Inc. Lowered by Analyst (NYSE:ABBV)

An analyst lowered AbbVie Inc.'s Q2 2024 EPS estimates, potentially influenced by market conditions, financial performance, or industry trends.

Q2 2024 EPS Estimates for AbbVie Lowered by Analyst

Zacks Research lowered their Q2 2024 EPS estimates for AbbVie to $2.98 from $3.01, with a consensus estimate of $11.26 per share for the full year. However, the company reported $2.31 earnings per share for Q2 2024, exceeding the consensus estimate of $2.26 by $0.05.

Analysts Update Price Targets for AbbVie

Several analysts updated their price targets for AbbVie, with Truist Financial lifting their price objective to $195.00, BMO Capital Markets cutting their price target to $180.00, Raymond James lifting their price target to $189.00, and Cantor Fitzgerald initiating coverage with a $200.00 price target.

AbbVie Inc. is an American biopharmaceutical company that focuses on discovering, developing, and delivering innovative medicines to solve complex health challenges. The company is committed to improving the lives of patients worldwide through its diverse portfolio of pharmaceutical drugs.

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

COM:ABBVIE

AbbVie Inc.

Last Close

174.43

12/11 19:50

Market Cap

296.91B

Beta: -

Volume Today

6.28M

Avg: -

Analysis Not Available